Friday, May 29, 2026

Policy

Policy•Fierce Biotech•May 28, 2026

FDA extends Beren’s rare disease review after info request, further stretching saga

background ▾

• •FDA classified Beren's data response as a major amendment, triggering a three-month extension of the review clock and signaling potential substantive deficiencies in the original filing.
• •The approval case rests entirely on OS comparison to external controls (84% vs. 42% at 5 years) rather than a randomized trial, which exposes the application to rejection given FDA's recent skepticism of natural history arms in rare disease approvals.
• •Monitor the November 17 decision date and any interim communications from Beren; rejection would likely require a new trial or stronger real-world evidence to overcome FDA's methodological concerns.

Beren TherapeuticsVtesseSucampoadrabetadex

→ Read original article

Policy•Fierce Pharma•May 29, 2026

Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge

background ▾

• •Global pharma executives are directly engaging with Japan's top leadership to reverse the country's declining biopharma R&D footprint and competitiveness.
• •Japan's share of global pharmaceutical research and development has been eroding, prompting industry to seek government policy support.
• •Watch for announcements of specific Japanese government policy changes around R&D incentives, tax benefits, regulatory streamlining, or innovation funding in coming months.

→ Read original article

Policy•Fierce Pharma•May 29, 2026

With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset

background ▾

• •AbbVie secures second FDA approval from ImmunoGen acquisition, strengthening ADC portfolio strategy
• •Elahere momentum combined with this new approval signals successful execution of ImmunoGen deal integration
• •Watch for commercial uptake trajectory of the newly approved asset and pipeline progression of remaining ImmunoGen candidates

AbbVieImmunoGenElaheremirvetuximab soravtansine

→ Read original article

Policy•STAT News•May 29, 2026

Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’

background ▾

• •Microdosing GLP-1s for weight loss lacks any rigorous clinical evidence and is primarily driven by direct-to-consumer compounded products without FDA approval, distinct from legitimate dose adjustments by medical professionals
• •FDA-approved GLP-1 therapies (semaglutide doses: 0.25–2.4 mg weekly or 1.5–25 mg daily; tirzepatide doses: 2.5–15 mg weekly) are the only doses rigorously studied for safety and efficacy; off-label microdosing exposes patients to unknown long-term risks
• •Watch for regulatory action against compounded GLP-1 products, physician-led guidelines on maintenance-phase dosing, and potential CMS/payer responses to off-label use patterns

semaglutideWegovyOzempic

→ Read original article

Policy•KFF•May 28, 2026

Medicare Advantage Out-of-Pocket Limits: Variation and Trends

background ▾

• •Medicare Advantage enrollees face substantial variation in out-of-pocket limits depending on plan type and state, with average limits significantly below statutory maximums, reflecting how plans allocate federal rebate dollars
• •HMO enrollees enjoy lower out-of-pocket caps than PPO enrollees despite narrower provider networks, creating a trade-off between access and financial protection
• •Traditional Medicare remains the only major U.S. health insurance form without an out-of-pocket cap; policymakers continue debating whether to add this protection as part of broader benefit redesign

→ Read original article

Market Access

Market Access•Fierce Biotech•May 28, 2026

Hoth Therapeutics’ pivot to AI in space sees stock rocket after rebrand

background ▾

• •Hoth Therapeutics has completely exited biopharmaceutical development and rebranded as Rocket One to pursue AI chip technology for orbital applications, with stock doubling on announcement.
• •The company's previous phase 2 data for an EGFR inhibitor-induced skin toxicity treatment and obesity-focused pipeline failed to attract investor support, prompting the drastic strategic pivot.

Hoth Therapeutics / Rocket OneSpaceXneurokinin 1 receptor agonist (EGFR inhibitor-induced skin toxicities)parenteral glial cell-derived neurotrophic factor

→ Read original article

Market Access•Fierce Biotech•May 28, 2026

Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals

background ▾

• •Novartis' $12B Avidity acquisition gives it three clinical-stage TFR-based therapies with demonstrated target engagement, including del-zota (DMD) approaching regulatory submission with 25% dystrophin increase data
• •The company is actively translating proven TFR muscle-targeting technology to neurodegenerative indications (Alzheimer's, Parkinson's) via partnerships with SciNeuro ($165M) and Arrowhead ($200M), though brain BBB tuning is acknowledged as more complex than muscle delivery
• •Competitive landscape intensifying: Roche advancing its own brain shuttle bispecific in Phase 3 and partnering with Manifold Bio; clinical readouts from Novartis' muscle programs in 2025 will signal likelihood of successful brain translatability and inform valuation of its broader BBB platform

NovartisSciNeuro PharmaceuticalsRochedelpacibart zotadirsendelpacibart etedesirandelpacibart braxlosiran

→ Read original article

Market Access•Fierce Pharma•May 29, 2026

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

background ▾

• •Imfinzi becomes the first-to-market PD-L1 inhibitor combination regimen approved for high-risk NMIBC, establishing a differentiated position versus Keytruda monotherapy in this patient population
• •This approval adds to AstraZeneca's growing bladder cancer franchise and demonstrates momentum in checkpoint inhibitor combinations across multiple indications
• •Monitor real-world uptake, payer reimbursement decisions, and whether Merck pursues combination strategies to remain competitive in the NMIBC segment

AstraZenecaMerckImfinzidurvalumabKeytruda

→ Read original article

Market Access•Fierce Pharma•May 29, 2026

CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo

background ▾

• •CVS Caremark's restoration of Zepbound coverage and addition of Foundayo removes a major market access barrier for Eli Lilly's obesity franchise, potentially affecting millions of insured patients
• •The move signals potential softening of PBM coverage restrictions on obesity medications, though formulary status and any associated restrictions (prior authorization, step therapy) remain unclear
• •Competitive dynamics with Novo Nordisk's Ozempic/Wegovy and other GLP-1 agents will likely continue to drive PBM coverage negotiations and formulary positioning

CVS CaremarkEli LillyZepboundFoundayo

→ Read original article

Market Access•Fierce Pharma•May 29, 2026

PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion

background ▾

• •PharmaEssentia is actively pursuing label expansion for Besremi with a dedicated commercialization leadership hire from a major oncology-focused pharma company
• •The appointment of a commercialization head with Incyte background suggests the company is preparing for multi-indication strategy execution

PharmaEssentiaIncyteBesremi

→ Read original article

Clinical Trials

No articles for this category on this date.